Medicine
Synarel 2 mg/mL nasal spray
Synarel 2 mg/mL nasal spray is a prescription medicine containing Nafarelin for nasal use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store upright at 25°C (77°F), excursions permitted to 15–30°C (59–86°F)…
Key facts
- Active ingredient (INN)
- Nafarelin
- Brand
- Synarel
- Strength
- 2 mg/mL
- Dosage form
- Nasal spray
- Route
- Nasal
- Packs
- 1 bottle
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories
- Origin register
- US FDA, United States
- Storage
- Store upright at 25°C (77°F), excursions permitted to 15–30°C (59–86°F). Protect from light. Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H01CA02 Nafarelin
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 February 1990
- Identifiers
- RxCUI 1797878, 1797880DailyMed set ID d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6NDC 0025-0166Application NDA019886
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle, spray in 1 carton / 8 mL in 1 bottle, spray | 0025-0166-08 | Pfizer Laboratories | 13 February 1990 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 13 February 1990 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Nafarelin is a gonadotropin releasing hormone receptor agonist indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. It is available as nasal spray. MedsAcross supplies Nafarelin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about NafarelinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Synarel prescribing information (Pfizer Laboratories) · U.S. National Library of Medicine, DailyMed
Need Synarel 2 mg/mL nasal spray for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.